Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Survival, Quality of Life and Self-reported Outcomes of Elderly Patients With Advanced Non-small Cell Lung Cancer Treated With Pembrolizumab (MK-3475) in the First Line Setting
Authors not listed
Spanish Lung Cancer Group · 2017
Abstract
This is a multi-center phase II trial of intravenous (IV) Pembrolizumab MK-3475 in subjects older than 70 years with advanced Non-small cell Lung Cancer (NSCLC) expressing Programmed death-ligand 1 (PD-L1). 82 patients will be enrolled in this trial to examine the efficacy, the impact on geriatric assessments, the quality of life and the self-reported outcomes.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-19 MST
Cite this
APA
Anonymous. (2017). Survival, Quality of Life and Self-reported Outcomes of Elderly Patients With Advanced Non-small Cell Lung Cancer Treated With Pembrolizumab (MK-3475) in the First Line Setting. <em>Spanish Lung Cancer Group</em>. https://clinicaltrials.gov/study/NCT03293680
Vancouver
Anonymous. Survival, Quality of Life and Self-reported Outcomes of Elderly Patients With Advanced Non-small Cell Lung Cancer Treated With Pembrolizumab (MK-3475) in the First Line Setting. Spanish Lung Cancer Group. 2017.
BibTeX
@misc{anon2017Surviv,
title = {Survival, Quality of Life and Self-reported Outcomes of Elderly Patients With Advanced Non-small Cell Lung Cancer Treated With Pembrolizumab (MK-3475) in the First Line Setting},
author = {Anonymous},
journal = {Spanish Lung Cancer Group},
year = {2017},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Shirish Gadgeel 2021
Open access · US-GOV
Phase II Study of Pemetrexed or Nab-paclitaxel With Pembrolizumab in Elderly (>/= 75 Years) Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Eli Lilly and Company 2006
Open access · US-GOV
A Phase II Trial Pemetrexed Carboplatin as First Line Chemotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC) in Elderly Patients
Hellenic Oncology Research Group 2010
Open access · US-GOV
First Line Treatment of Elderly Patients With Advanced or Metastatic NSCLC With Docetaxel and Bevacizumab
Grupo de Investigación y Divulgación Oncológica 2013
Open access · US-GOV
Phase II Trial of Geriatric Evaluation as Selection Criteria and Predictive Factor of Safety in Elderly Patients (≥ 70 Years) With Non-small Cell Lung Cancer (NSCLC)That Can be Treated With Bevacizumab, Carboplatin and Paclitaxel
Fox Chase Cancer Center 2007
Open access · US-GOV
Phase II Study of Bevacizumab and Erlotinib in Elderly Patients With Advanced Non-Small Lung Cancer
The First Affiliated Hospital of Xiamen University 2021
Open access · US-GOV